Showing Results for
- Academic Journals (71)
Search Results
- 71
Academic Journals
- 71
- Search Terms:
- 1From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedAbbott Laboratories has made a bid for a slice of the multiple sclerosis (MS) market, through its $450 million cash acquisition of Facet Biotech. The deal, announced in March, gives Abbott a stake in Zenapax...
- 2From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedCrops with superior agricultural traits can often be created by crossing different varieties, but few examples exist of single genes that determine the genetic basis of this effect, known as heterosis. These so-called...
- 3From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedThe US Court of Appeals for the Federal Curcuit in March ruled for Eli Lilly in Indianapolis, Indiana, and against Ariad Pharmaceuticals, affirming an earlier decision by a three-judge panel and dealing a possible death...
- 4From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedXcellerex (Marlborough, MA, USA) has named Guy Broadbent president, CEO and a member of the company's board of directors. He succeeds Joseph Zakrzewski, who served as chairman, president and CEO, as part of an existing...
- 5From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedRobert M. Whelan has been appointed to the board of directors of ARIAD Pharmaceuticals (Cambridge, MA, USA). He has more than 35 years of corporate finance and investment banking experience, including leadership...
- 6From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedMassively parallel cDNA sequencing (RNA-Seq) provides an unbiased way to study a transcriptome, including both coding and noncoding genes. Until now, most RNA-Seq studies have depended crucially on existing annotations...
- 7From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedIt was unseasonably cold in Florida during the Advances in Genome Biology and Technology (AGBT) meeting on Marco Island, on 24-27 February, but there was no cooling the enthusiasm and excitement of meeting participants...
- 8From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedBiotech stocks remain buoyant, and although funding dipped compared with the preceding two quarters, 1Q09 remained above the dire levels seen last winter. Excluding US partnership monies, the industry pulled in $5.5...
- 9From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-Reviewed"Right now your family history may be your best bet and it doesn't cost anything," Francis Collins, director of the US National Institutes of Health and leader of the Human Genome Project, downplays the impact of...
- 10From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedQLT (Vancouver) has announced that Dipak Panigrahi has joined the company as senior vice president, R&D and chief medical officer. Most recently, he was vice president, glaucoma development at Alcon Laboratories....
- 11From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedThe Predictive Safety Testing Consortium's first regulatory submission to qualify kidney safety biomarkers revealed two deficiencies. To address the need for biomarkers that monitor recovery from agent-induced renal...
- 12From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedThe board of directors of Karo Bio (Stockholm) has appointed Fredrik Lindgren (left) as president and CEO. He succeeds Per Olof Wallstrom, who announced his resignation in February. Lindgren has taken on positions of...
- 13From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedTo the Editor: Compositional equivalence of crops improved through biotech-derived transgenic, or genetically modified (GM), traits and their conventional (non-GM) comparators is an important criterion in breeding as...
- 14From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedRNA-based drug developer AVI BioPharma (Bothell, WA, USA) has appointed its CFO J. David Boyle II to the additional role of interim president and CEO, after the resignation of Leslie Hudson as president, CEO and a...
- 15From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedPrivately held Liquidia Technologies (Research Triangle Park, NC, USA) has appointed Jonathan F. Smith as CSO. Smith is a co-founder and previously served as CSO of AlphaVax....
- 16From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-Reviewed"Merck is now a bigger beast to feed." Merck's Margaret Beer urges biotechs gathered at a recent conference in London to approach the newly expanded company, as it is still actively searching for opportunities....
- 17From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedThe study of induced pluripotency often relies on experimental approaches that average measurements across a large population of cells, the majority of which do not become pluripotent. Here we used high-resolution,...
- 18From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedCarel du Marchie Sarvaas has joined EuropaBio (Brussels) as director for agricultural biotech, taking over from Morten Nielsen, who has led the division team since September 2009. He brings to EuropaBio his experience...
- 19From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedCytokine storm is a destructive overreaction of the innate immune system to infections or other conditions. When produced in excess, inflammatory cytokines can lead to vascular leakage, tissue edema, organ failure,...
- 20From: Nature Biotechnology. (Vol. 28, Issue 5) Peer-ReviewedOn March 29, the sound of sabres rattling loudly emanated from a local court in the Southern District of New York. In a case that involved the BRCA1 and BRCA2 genetic tests for familial breast and ovarian cancer...